Expression analysis and functional assays reveals that GBM cells elevate their TNFRSF14 expression under IFN-γ (type II IFN signaling), instead of IFN-α or IFN-β (type I IFN signaling) stimulation, which enhances their proliferation and in vivo tumorigenicity. The gene discussed is IFNB1; the disease is glioblastoma.